Trial Profile
Fifty-Two Weeks, Open Label Extension Trial to Evaluate Safety and Efficacy of Org 50081 in Outpatients With Chronic Primary Insomnia Who Completed Clinical Trial Protocol 176001 or 176002
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 09 May 2022
Price :
$35
*
At a glance
- Drugs Esmirtazapine (Primary)
- Indications Insomnia
- Focus Adverse reactions
- Sponsors Merck Sharp & Dohme
- 20 Jan 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 20 Jan 2010 Actual end date (Aug 2009) added as reported by ClinicalTrials.gov.
- 09 Oct 2009 Schering-Plough added as trial sponsor and affiliate as reported by ClinicalTrials.gov.